Double-dipping on ProSkelia

When Galapagos N.V. was formed in 1999 as a functional genomics-focused joint venture between Introgene B.V. and Tibotec N.V., the idea was to combine Introgene's adenoviral vector technology with Tibotec's high throughput screening technology as a faster way to find gene function, particularly in the cardiovascular area. The resulting novel targets then would be licensed to pharma companies.

But such service businesses have never covered enough of the value chain to be sustainable, and so, along with virtually all of its surviving brethren from the genomics bubble, Galapagos has gradually moved into drug development. ...